Vaccine to Reduce Campylobacter Jejuni in Chickens

Technology #ua12-023

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Lynn Joens
Professor, Veterinary Science & Microbiology
Bibiana Law
Assistant Research Professor, Veterinary Science & Microbiology
Alexandra Armstrong
Assistant Research Scientist, Veterinary Science & Microbiology
Managed By
Tod McCauley
Sr. Licensing Manager (520) 626-7916

Background: Campylobacteriosis is currently the number two bacterial food-borne disease in the U.S. and is responsible for an estimated 2.4 million illnesses per year. The handling and consumption of poultry is considered to be the most significant risk factor in transmission. To date, there is no vaccine available to the producer to reduce numbers of Campylobacter from poultry going to processing. Due to the emergence and persistence of antibiotic resistance coupled with increasing regulatory restrictions on the industry, control strategies such as vaccination are urgently needed. The most promising results to date have been achieved using attenuated Salmonella vectors to deliver C. jejuni antigens. Using a newly identified putative immunogenic protein from an extract of C. jejuni. University of Arizona investigators have demonstrated reduced numbers of C. jejuni in vaccinated birds after challenge compared to non-vaccinated controls.



·         A Salmonella vectored vaccine that can inhibit C. jejuni colonization in immunized birds.

·         Successful vaccination of chickens would lead to compliance of the new FSIS performance standards for Campylobacter in chickens.



  • Method is safe, cost effective, and highly efficacious, preventing campylobacteriosis.
  • A novel gene identified as an effective vaccine target that stimulates a strong immune response in chicks.
  • Vaccine can be cost-effectively produced at commercial scale.
  • The vector used is attenuated and, therefore, not detectable 6 days following vaccination.
  • Safety concerns for chicks, caretakers, and consumers are alleviated.


Stage of Development: Vaccine delivery method and dosage efficacy studies underway.


Refer to case number UA12-023